14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs MAZE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Captures Overall Composite Edge (57.8 HOLD vs 34.8 SELL), While MAZE Leads 3–2 on Growth & Valuation Pillars
VOR Overall Winner
6-Pillar Tally: VOR 2 – 3 MAZE (1 Tie)
Matrix Metrics: VOR 4 – 4 MAZE
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Maze Therapeutics, Inc. (MAZE) on higher Unified Composite conviction (57.8/100 HOLD vs. 34.8/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while MAZE wins 3–2 across the 6-pillar growth and valuation breakdown. VOR trades at $19.26 (N/M Forward P/E, 0.0% operating margin) versus MAZE at $34.16 (8.5x Forward P/E, -820.8% operating margin).
Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. MAZE 34.8/100 SELL) and 1.91β · 61% Vol risk profile, whereas MAZE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs MAZE. Trailing 12-month operating profitability (VOR 0.0% vs MAZE -820.8%) and valuation multiples (VOR N/M vs MAZE 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.0B market capitalization and -820.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VOR vs MAZE Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Maze Therapeutics, Inc. (MAZE) on higher Unified Composite conviction (57.8/100 HOLD vs. 34.8/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while MAZE wins 3–2 across the 6-pillar growth and valuation breakdown. VOR trades at $19.26 (N/M Forward P/E, 0.0% operating margin) versus MAZE at $34.16 (8.5x Forward P/E, -820.8% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (57.8/100 HOLD vs. MAZE 34.8/100 SELL) and 1.91β · 61% Vol risk profile, whereas MAZE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
MAZE leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MAZE at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (100.0% gross margin, -820.8% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $20M for MAZE. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MAZE.
MAZE screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MAZE trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 98.7x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus MAZE (-37.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk). By comparison, MAZE carries 96.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.78β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.